will present preliminary two-year BMD results from a one-year extension. Objectives Methods We compared the efficacy of treatment with OW ALN 70 mg (n = 519), TW ALN 35 mg (n = 369), and OD ALN 10 mg (n = 370) over 2 years in a double-blind, multicenter study of postmenopausal women (age 40 to 90) with osteoporosis (BMD of either the lumbar spine or femoral neck !2.5 SDs below peak mean, or prior vertebral or hip fracture). The primary efficacy endpoint was change in lumbar spine BMD. Secondary

more »

... endpoints included changes in BMD at the hip and total body. Results Mean BMD increases at the lumbar spine, total hip, femoral neck, hip trochanter, and total body sites for each treatment regimen after two years were very similar, with no clinically meaningful differences. Conclusion These findings confirm that once-weekly ALN 70 mg is therapeutically equivalent to once-daily ALN 10 mg in patients with postmenopausal osteoporosis. In addition, the twoyear results demonstrate that once-weekly ALN 70 mg is generally as safe and well tolerated as ALN 10 mg once daily.